Burnaby, BC, December 12, 2022--Response Biomedical Corp. (Response), a global provider of acute care diagnostic testing solutions, announced that Health Canada has granted the RAMP COVID-19 Antigen Test authorization to commercialize under the Emergency Use Interim Order. The Health Canada authorization allows Response to market and sell the RAMP COVID-19 Antigen Test to countries that recognize Health Canada authorization.
|